South Korea · Delayed Price · Currency is KRW Daehan Nupharm Statistics
Total Valuation
Daehan Nupharm has a market cap or net worth of KRW 78.46 billion. The enterprise value is 141.79 billion.
| Market Cap | 78.46B |
| Enterprise Value | 141.79B |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | Dec 29, 2025 |
Share Statistics
Daehan Nupharm has 14.04 million shares outstanding.
| Current Share Class | 14.04M |
| Shares Outstanding | 14.04M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 39.90% |
| Owned by Institutions (%) | 0.31% |
| Float | 8.15M |
Valuation Ratios
The trailing PE ratio is 3.28.
| PE Ratio | 3.28 |
| Forward PE | n/a |
| PS Ratio | 0.37 |
| PB Ratio | 0.53 |
| P/TBV Ratio | 0.53 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 13.24 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 5.92 |
| EV / Sales | 0.67 |
| EV / EBITDA | 9.93 |
| EV / EBIT | 14.92 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.76, with a Debt / Equity ratio of 0.71.
| Current Ratio | 1.76 |
| Quick Ratio | 1.12 |
| Debt / Equity | 0.71 |
| Debt / EBITDA | 7.35 |
| Debt / FCF | -5.05 |
| Interest Coverage | 5.44 |
Financial Efficiency
Return on equity (ROE) is 17.36% and return on invested capital (ROIC) is 4.24%.
| Return on Equity (ROE) | 17.36% |
| Return on Assets (ROA) | 2.35% |
| Return on Invested Capital (ROIC) | 4.24% |
| Return on Capital Employed (ROCE) | 4.64% |
| Weighted Average Cost of Capital (WACC) | 3.07% |
| Revenue Per Employee | 927.56M |
| Profits Per Employee | 104.97M |
| Employee Count | 228 |
| Asset Turnover | 0.82 |
| Inventory Turnover | 2.95 |
Taxes
In the past 12 months, Daehan Nupharm has paid 1.90 billion in taxes.
| Income Tax | 1.90B |
| Effective Tax Rate | 7.34% |
Stock Price Statistics
The stock price has decreased by -19.80% in the last 52 weeks. The beta is 0.16, so Daehan Nupharm's price volatility has been lower than the market average.
| Beta (5Y) | 0.16 |
| 52-Week Price Change | -19.80% |
| 50-Day Moving Average | 5,622.20 |
| 200-Day Moving Average | 6,353.35 |
| Relative Strength Index (RSI) | 43.93 |
| Average Volume (20 Days) | 16,111 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Daehan Nupharm had revenue of KRW 211.48 billion and earned 23.93 billion in profits.
| Revenue | 211.48B |
| Gross Profit | 88.94B |
| Operating Income | 9.71B |
| Pretax Income | 25.83B |
| Net Income | 23.93B |
| EBITDA | 14.48B |
| EBIT | 9.71B |
| Earnings Per Share (EPS) | n/a |
Balance Sheet
The company has 43.12 billion in cash and 106.45 billion in debt, with a net cash position of -63.33 billion or -4,512.43 per share.
| Cash & Cash Equivalents | 43.12B |
| Total Debt | 106.45B |
| Net Cash | -63.33B |
| Net Cash Per Share | -4,512.43 |
| Equity (Book Value) | 148.94B |
| Book Value Per Share | n/a |
| Working Capital | 54.84B |
Cash Flow
In the last 12 months, operating cash flow was 5.93 billion and capital expenditures -26.99 billion, giving a free cash flow of -21.07 billion.
| Operating Cash Flow | 5.93B |
| Capital Expenditures | -26.99B |
| Depreciation & Amortization | 4.77B |
| Net Borrowing | 24.03B |
| Free Cash Flow | -21.07B |
| FCF Per Share | -1,500.92 |
Margins
Gross margin is 42.05%, with operating and profit margins of 4.59% and 11.32%.
| Gross Margin | 42.05% |
| Operating Margin | 4.59% |
| Pretax Margin | 12.21% |
| Profit Margin | 11.32% |
| EBITDA Margin | 6.85% |
| EBIT Margin | 4.59% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 100.00, which amounts to a dividend yield of 1.77%.
| Dividend Per Share | 100.00 |
| Dividend Yield | 1.77% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 5.86% |
| Buyback Yield | n/a |
| Shareholder Yield | 1.77% |
| Earnings Yield | 30.50% |
| FCF Yield | -26.85% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Daehan Nupharm has an Altman Z-Score of 1.94 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.94 |
| Piotroski F-Score | 4 |